

Endocrinology and Diabetes

Director OISO, Yutaka (Professor)

12W

Professional diagnosis and treatment of diabetes and endocrine disease

We are energetically involved in the diagnosis and treatment of diabetes and a wide range of endocrine diseases.

Medical Care System

Our department has 32 consulting doctors, 11 diabetologists, three supervising doctor, seven endocrine specialists, and three supervising doctors; we provide medical care every day in five examination rooms in the outpatient clinic and 22 beds in the inpatient department.

Target Disease

Pituitary disease (e.g. acromegaly, Cushing's disease, hypopituitarism, diabetes insipidus), thyroid disease (e.g. Basedow's disease, Hashimoto's disease), adrenal disease (e.g. Cushing's syndrome, primary hyperaldosteronism, pheochromocytoma), diabetes, and diabetic complications.

Strong Fields

We perform professional diagnosis and treatment of all endocrine diseases such as diabetes insipidus. As for thyroid diseases, we perform echo-guided fine-needle aspiration cytology; for Basedow's disease, we perform internal radiation therapy and retro-orbital radiation in cooperation with Radiology. For diabetes, we conduct blood sugar control that incorporates insulin pump therapy (CSII) and continuous glucose monitoring (CGM). Also, we promote the treatment of diabetes through a comprehensive approach based on team medical care for diabetes in cooperation with nurses, pharmacists, registered dietitians, and physical therapists.

Clinical Results

The number of outpatients (total number) is about 28,000 a year; the number of inpatients (total number) is about 350 a year.

Specialized Outpatient Clinic

For medical care for endocrine disease, we perform a professional diagnosis and treatment in all pituitary, thyroid, and adrenal diseases. For medical care for diabetes, we are actively involved in providing recuperation guidance such as nutritional guidance and foot care.

Advanced Medicine and Research

We conduct research on central diabetes insipidus, obesity, new therapies for SIADH, lymphocytic hypophysitis, and functions of pancreatic β cells, fat cells, and intestinal tract in diabetes.



Nephrology

Director MARUYAMA, Shoichi (Extraordinary Professor)

10E

We provide medical care for all diseases related to the kidney with the latest therapies

We treat various renal diseases after carefully examining information based on accurate evidence and obtaining full understanding from the patient and family.

Medical Care System

Our department consists of about 15 full-time and part-time doctors. Medical care is provided mainly by professors who are nephrology specialists. We hold a conference twice a week and determine the course of treatment.

Target Disease

All diseases related to the kidney including renal disease such as nephritis, nephrotic syndrome, renal failure, hypertensive renal disorder, diabetic nephropathy, collagen disorder, systemic vasculitis syndrome and management after renal transplantation and electrolyte and acid-base balance disorder.

Strong Fields

We are actively involved in renal pathological diagnosis, renal replacement therapy, and new immunosuppressive therapies using ciclosporin, tacrolimus, etc. and alpha-glucosidase replacement therapy for diseases such as refractory nephrotic syndrome, collagen disorder, and hereditary diseases.

Clinical Results

Annual number of inpatients: 323; number of pathological diagnosis by renal biopsy: 608 (our hospital: 47, affiliated facilities: 561); number of patients in whom dialysis was newly introduced: 35 (hemodialysis: 24, peritoneal dialysis 11); other patients (plasma exchange therapy and selective blood cell component adsorption therapy; total number of patients: 287).

Specialized Outpatient Clinic

Outpatient clinic for peritoneal dialysis and outpatient clinic for chronic kidney disease (CKD).

Advanced Medicine and Research

We are involved in laparoscopic renal biopsy (in cooperation with Urology) for high-risk patients, research on renal regeneration using adipose stem cells, development of urinary biomarkers for acute renal disorders, development of antihypertensive drugs using RAS inhibitory molecules, and elucidation of the mechanism of peritoneal fibrosis.

